Bausch settles $300m antitrust case over diabetes drug price hikes

Canadian pharma firm Bausch Health has agreed to settle an antitrust suit where it was accused of holding an illegal monopoly on the diabetes drug Glumetza (metformin hcl).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Generics

Pharmavite accuses Bausch, GSK of ‘sham’ patent litigation

13 December 2021 Nutritional supplements manufacturer Pharmavite has filed an antitrust suit against Bausch & Lomb and GlaxoSmithKline, claiming that they are filing sham patent litigation related to its “PreserVision” products.

Americas

Bausch Health resolves IBS patent litigation

7 May 2020 Canada-based Bausch Health has agreed to settle its dispute with generic maker Sandoz over the latter’s attempt to release a generic version of antibiotic Xifaxan.

Americas

Bausch Health resolves IP litigation with Teva

2 August 2019 Canadian pharmaceutical company Bausch Health and generics maker Teva have resolved their dispute over Apriso (mesalazine), a drug used to treat ulcerative colitis and Crohn's disease.

More on this story

Generics

Pharmavite accuses Bausch, GSK of ‘sham’ patent litigation

Americas

Bausch Health resolves IBS patent litigation

7 May 2020 Canada-based Bausch Health has agreed to settle its dispute with generic maker Sandoz over the latter’s attempt to release a generic version of antibiotic Xifaxan.

Americas

Bausch Health resolves IP litigation with Teva

2 August 2019 Canadian pharmaceutical company Bausch Health and generics maker Teva have resolved their dispute over Apriso (mesalazine), a drug used to treat ulcerative colitis and Crohn's disease.

More on this story

Generics

Pharmavite accuses Bausch, GSK of ‘sham’ patent litigation

Americas

Bausch Health resolves IBS patent litigation

7 May 2020 Canada-based Bausch Health has agreed to settle its dispute with generic maker Sandoz over the latter’s attempt to release a generic version of antibiotic Xifaxan.

Americas

Bausch Health resolves IP litigation with Teva

2 August 2019 Canadian pharmaceutical company Bausch Health and generics maker Teva have resolved their dispute over Apriso (mesalazine), a drug used to treat ulcerative colitis and Crohn's disease.

More features

Life sciences leaders recognised at LSPN Awards USA 2025

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

LSPN: Counsel grapple with AI’s impact on training and critical thinking

'Nothing can stand in the way of our work': Ukraine resumes IP system

LSPN: Trump's policy storm causing chaos and confusion

Taylor Wessing expands in Europe with Paris team

LSPN: Using ‘the patentee’s friend’ in Section 112 claims

ResMed voids sleep apnoea tech patent at PTAB

Bausch settles $300m antitrust case over diabetes drug price hikes

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features